Associations - epirubicin

No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	ifosfamide + epirubicin + mesna Sensitive: A2 - Guideline ifosfamide + epirubicin + mesna Sensitive : A2	ifosfamide + epirubicin + mesna Sensitive: A2 - Guideline ifosfamide + epirubicin + mesna Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	cisplatin + paclitaxel + epirubicin Sensitive: A2 - Guideline cisplatin + paclitaxel + epirubicin Sensitive : A2	cisplatin + paclitaxel + epirubicin Sensitive: A2 - Guideline cisplatin + paclitaxel + epirubicin Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2
MSH3 overexpression	Soft Tissue Sarcoma	MSH3 overexpression	Soft Tissue Sarcoma	ifosfamide + epirubicin Resistant: B - Late Trials ifosfamide + epirubicin Resistant : B	ifosfamide + epirubicin Resistant: B - Late Trials ifosfamide + epirubicin Resistant : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	paclitaxel + cyclophosphamide + epirubicin Sensitive: B - Late Trials paclitaxel + cyclophosphamide + epirubicin Sensitive : B	paclitaxel + cyclophosphamide + epirubicin Sensitive: B - Late Trials paclitaxel + cyclophosphamide + epirubicin Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	epirubicin Sensitive: C2 – Inclusion Criteria epirubicin Sensitive : C2	epirubicin Sensitive: C2 – Inclusion Criteria epirubicin Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	epirubicin + vinorelbine tartrate Sensitive: C3 – Early Trials epirubicin + vinorelbine tartrate Sensitive : C3	epirubicin + vinorelbine tartrate Sensitive: C3 – Early Trials epirubicin + vinorelbine tartrate Sensitive : C3
UNC13D mutation	HER2 Negative Breast Cancer	UNC13D mutation	HER2 Negative Breast Cancer	epirubicin + vinorelbine tartrate Sensitive: C3 – Early Trials epirubicin + vinorelbine tartrate Sensitive : C3	epirubicin + vinorelbine tartrate Sensitive: C3 – Early Trials epirubicin + vinorelbine tartrate Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	docetaxel + epirubicin Sensitive: C3 – Early Trials docetaxel + epirubicin Sensitive : C3	docetaxel + epirubicin Sensitive: C3 – Early Trials docetaxel + epirubicin Sensitive : C3
KMT2D mutation	Triple Negative Breast Cancer	KMT2D mutation	Triple Negative Breast Cancer	cyclophosphamide + epirubicin Resistant: C3 – Early Trials cyclophosphamide + epirubicin Resistant : C3	cyclophosphamide + epirubicin Resistant: C3 – Early Trials cyclophosphamide + epirubicin Resistant : C3
CD8 overexpression	Breast Cancer	CD8 overexpression	Breast Cancer	paclitaxel + epirubicin Sensitive: C3 – Early Trials paclitaxel + epirubicin Sensitive : C3	paclitaxel + epirubicin Sensitive: C3 – Early Trials paclitaxel + epirubicin Sensitive : C3
TMEM225B rs10273424	Breast Cancer	TMEM225B rs10273424	Breast Cancer	docetaxel + epirubicin Resistant: C3 – Early Trials docetaxel + epirubicin Resistant : C3	docetaxel + epirubicin Resistant: C3 – Early Trials docetaxel + epirubicin Resistant : C3
SLCO1B1 rs2306283	Breast Cancer	SLCO1B1 rs2306283	Breast Cancer	docetaxel + epirubicin Resistant: C3 – Early Trials docetaxel + epirubicin Resistant : C3	docetaxel + epirubicin Resistant: C3 – Early Trials docetaxel + epirubicin Resistant : C3
GSTP1 rs1138272	Breast Cancer	GSTP1 rs1138272	Breast Cancer	docetaxel + epirubicin Resistant: C3 – Early Trials docetaxel + epirubicin Resistant : C3	docetaxel + epirubicin Resistant: C3 – Early Trials docetaxel + epirubicin Resistant : C3
ER negative	Breast Cancer	ER negative	Breast Cancer	albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive: C3 – Early Trials albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive : C3	albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive: C3 – Early Trials albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive : C3
TOP2A amplification	Breast Cancer	TOP2A amplification	Breast Cancer	epirubicin Sensitive: C3 – Early Trials epirubicin Sensitive : C3	epirubicin Sensitive: C3 – Early Trials epirubicin Sensitive : C3
TOP2A deletion	Breast Cancer	TOP2A deletion	Breast Cancer	epirubicin Sensitive: C3 – Early Trials epirubicin Sensitive : C3	epirubicin Sensitive: C3 – Early Trials epirubicin Sensitive : C3
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive: C3 – Early Trials albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive : C3	albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive: C3 – Early Trials albumin-bound paclitaxel + cyclophosphamide + epirubicin Sensitive : C3
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	albumin-bound paclitaxel + cyclophosphamide + epirubicin + pegfilgrastim Sensitive: C3 – Early Trials albumin-bound paclitaxel + cyclophosphamide + epirubicin + pegfilgrastim Sensitive : C3	albumin-bound paclitaxel + cyclophosphamide + epirubicin + pegfilgrastim Sensitive: C3 – Early Trials albumin-bound paclitaxel + cyclophosphamide + epirubicin + pegfilgrastim Sensitive : C3
CDH1 mutation	Breast Cancer	CDH1 mutation	Breast Cancer	paclitaxel + epirubicin Resistant: C3 – Early Trials paclitaxel + epirubicin Resistant : C3	paclitaxel + epirubicin Resistant: C3 – Early Trials paclitaxel + epirubicin Resistant : C3
TMB-H + PD-L1 overexpression	Fibrosarcoma	TMB-H + PD-L1 overexpression	Fibrosarcoma	cisplatin + ifosfamide + epirubicin Resistant: C4 – Case Studies cisplatin + ifosfamide + epirubicin Resistant : C4	cisplatin + ifosfamide + epirubicin Resistant: C4 – Case Studies cisplatin + ifosfamide + epirubicin Resistant : C4
NCOR2 overexpression	Breast Cancer	NCOR2 overexpression	Breast Cancer	epirubicin Resistant: D – Preclinical epirubicin Resistant : D	epirubicin Resistant: D – Preclinical epirubicin Resistant : D
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	epirubicin Resistant: D – Preclinical epirubicin Resistant : D	epirubicin Resistant: D – Preclinical epirubicin Resistant : D
SEMA6D underexpression	Breast Cancer	SEMA6D underexpression	Breast Cancer	epirubicin Resistant: D – Preclinical epirubicin Resistant : D	epirubicin Resistant: D – Preclinical epirubicin Resistant : D
TOP2A overexpression	Rectal Cancer	TOP2A overexpression	Rectal Cancer	epirubicin Resistant: D – Preclinical epirubicin Resistant : D	epirubicin Resistant: D – Preclinical epirubicin Resistant : D
TOP2A amplification	Rectal Cancer	TOP2A amplification	Rectal Cancer	epirubicin Resistant: D – Preclinical epirubicin Resistant : D	epirubicin Resistant: D – Preclinical epirubicin Resistant : D
TP73 overexpression	Multiple Myeloma	TP73 overexpression	Multiple Myeloma	epirubicin Sensitive: D – Preclinical epirubicin Sensitive : D	epirubicin Sensitive: D – Preclinical epirubicin Sensitive : D

epirubicin

Associations
(29)

Associations
(29)

epirubicin

Associations(29)

Associations(29)

Associations
(29)

Associations
(29)